Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
Titel:
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
Auteur:
Boilève, Alice Hilmi, Marc Gougis, Paul Cohen, Romain Rousseau, Benoît Blanc, Jean-Frédéric Ben Abdelghani, Meher Castanié, Hélène Dahan, Laëtitia Tougeron, David Metges, Jean-Philippe Tournigand, Christophe Garcia-Larnicol, Marie-Line Vernerey, Dewi Turpin, Anthony Neuzillet, Cindy